Home-administered transcranial direct current stimulation is a feasible intervention for depression: an observational cohort study.
depression
digital health
home-based tDCS
major depressive disorder
non-invasive brain stimulation
telehealth
transcranial direct current stimulation (tDCS)
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
04
2023
accepted:
25
07
2023
medline:
7
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
Transcranial direct current stimulation (tDCS) is an emerging treatment for major depression. We recruited participants with moderate-to-severe major depressive episodes for an observational clinical trial using Soterix Medical's tDCS telehealth platform as a standard of care. The acute intervention consisted of 28 sessions (5 sessions/week, 6 weeks) of the left anodal dorsolateral prefrontal cortex (DLPFC) tDCS (2.0 mA × 30 min) followed by a tapering phase of weekly sessions for 4 weeks (weeks 7-10). The
Identifiants
pubmed: 37674552
doi: 10.3389/fpsyt.2023.1199773
pmc: PMC10477781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1199773Informations de copyright
Copyright © 2023 Charvet, George, Charlson, Lustberg, Vogel-Eyny, Eilam-Stock, Cho, Best, Fernandez, Datta, Bikson, Nazim and Pilloni.
Déclaration de conflit d'intérêts
The City University of New York holds patents on brain stimulation with MB and AD as inventors. MB has equity in Soterix Medical Inc., consulted, received grants, assigned inventions, and/or served on the SAB of SafeToddles, Boston Scientific, GlaxoSmithKline, Biovisics, Mecta, Lumenis, Halo Neuroscience, Google-X, i-Lumen, Humm, Allergan (Abbvie), Apple, Ybrain, Ceragem, and Remz. LC has consulted for Ybrain, Neuroelectrics, Johnson & Johnson, and Biogen. AD and KN are employees of Soterix Medical Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Pharmacol. 2013 Apr 16;4:45
pubmed: 23596418
Depress Anxiety. 2020 Jul;37(7):594-608
pubmed: 32101631
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
JMIR Ment Health. 2022 Sep 20;9(9):e40924
pubmed: 36125880
Brain Stimul. 2022 May-Jun;15(3):707-716
pubmed: 35470019
Psychopharmacol Bull. 1993;29(2):321-6
pubmed: 8290681
J Affect Disord. 2019 Jun 1;252:475-483
pubmed: 31005790
Neuropsychiatr Dis Treat. 2020 Jan 21;16:221-234
pubmed: 32021216
Brain Stimul. 2020 Jul - Aug;13(4):1124-1149
pubmed: 32413554
Int Clin Psychopharmacol. 2009 May;24(3):133-8
pubmed: 19318972
Clin Neurophysiol. 2013 Mar;124(3):551-6
pubmed: 23031743
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Biol Psychiatry. 2003 Sep 1;54(5):573-83
pubmed: 12946886
Psychiatry Res. 2021 Aug;302:114024
pubmed: 34058716
Eur Arch Psychiatry Clin Neurosci. 2023 Aug;273(5):1151-1161
pubmed: 36253582
Brain Stimul. 2020 May - Jun;13(3):686-693
pubmed: 32289698
Brain Stimul. 2015 May-Jun;8(3):590-602
pubmed: 25862601
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Int J Neuropsychopharmacol. 2021 Apr 21;24(4):256-313
pubmed: 32710772
Int J Clin Health Psychol. 2023 Jul-Sep;23(3):100369
pubmed: 36817875
Clin Neurophysiol. 2022 Nov;143:154-165
pubmed: 36115809